Sign in

Daniel Scott Harriman

Research Analyst at Sidoti & Company

Daniel Scott Harriman is an Equity Research Analyst at Sidoti & Company, specializing in small- and micro-cap equities with a focus on industrials and specialty chemicals. His research coverage includes companies such as Hawkins, Inc. and HF Foods, providing in-depth analysis and industry forecasts that inform institutional investors. Harriman has progressed within Sidoti & Company, taking on lead coverage responsibilities for multiple publicly-traded firms and contributing to the firm’s sector research team since joining. He holds required FINRA securities licenses in connection with his analyst role, underscoring his professional credentials and regulatory compliance.

Daniel Scott Harriman's questions to BALCHEM (BCPC) leadership

Question · Q3 2025

Daniel Scott Harriman asked for a breakdown of the 7.5% year-over-year growth within the Specialty Products segment, specifically differentiating between performance gases and plant nutrition. He also requested more information on the success of Balchem's geographic expansion efforts within the plant nutrition business.

Answer

Chairman, President, and CEO Ted Harris detailed that the Specialty Products segment grew 7.5% overall, with performance gases growing 7% and plant nutrition growing 13%. He noted that performance gases, traditionally a lower-growth business, has stabilized and is seeing nice growth, particularly in Europe. For plant nutrition, Mr. Harris highlighted successful international expansion, especially in Latin America (e.g., Brazil) and Asia Pacific (e.g., India). This expansion helps balance the seasonality experienced in the U.S. market, where the business has been relatively flat, with international sales driving the majority of the growth.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts